Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.

Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, Jöhrer K.

J Hematol Oncol. 2016 Nov 3;9(1):116.

2.

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.

Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K.

Oncotarget. 2016 Nov 29;7(48):78605-78618. doi: 10.18632/oncotarget.12522.

3.

Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.

Ganghammer S, Gutjahr J, Hutterer E, Krenn PW, Pucher S, Zelle-Rieser C, Jöhrer K, Wijtmans M, Leurs R, Smit MJ, Gattei V, Greil R, Hartmann TN.

Haematologica. 2016 Mar;101(3):e99-102. doi: 10.3324/haematol.2015.133470. Epub 2015 Nov 20. No abstract available.

4.

Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma--an analysis from the Austrian Myeloma Registry.

Willenbacher W, Willenbacher E, Zelle-Rieser C, Biedermann R, Weger R, Jöhrer K, Brunner A.

Leuk Lymphoma. 2016;57(6):1478-81. doi: 10.3109/10428194.2015.1099646. Epub 2015 Nov 16. No abstract available.

PMID:
26413883
5.

Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?

Jöhrer K, Hofbauer SW, Zelle-Rieser C, Greil R, Hartmann TN.

Expert Opin Biol Ther. 2012 Apr;12(4):425-41. doi: 10.1517/14712598.2012.664128. Epub 2012 Feb 15. Review.

PMID:
22332909
6.

Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Jöhrer K, Obkircher M, Neureiter D, Parteli J, Zelle-Rieser C, Maizner E, Kern J, Hermann M, Hamacher F, Merkel O, Wacht N, Zidorn C, Scheideler M, Greil R.

J Mol Med (Berl). 2012 Jun;90(6):681-93. doi: 10.1007/s00109-011-0848-x. Epub 2011 Dec 29.

PMID:
22205266
7.

Tumour-immune cell interactions modulated by chemokines.

Jöhrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R.

Expert Opin Biol Ther. 2008 Mar;8(3):269-90. doi: 10.1517/14712598.8.3.269 . Review.

PMID:
18294099
8.

Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.

Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M.

Cancer Immunol Immunother. 2005 Jul;54(7):663-70. Epub 2004 Dec 17.

PMID:
15918076
9.

Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.

Jöhrer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, Gander H, Höltl L, Bartsch G, Greil R, Thurnher M.

Clin Cancer Res. 2005 Apr 1;11(7):2459-65.

10.

Generation of clinical-grade monocyte-derived dendritic cells using the CliniMACS system.

Putz T, Gander H, Ramoner R, Zelle-Rieser C, Rahm A, Nussbaumer W, Bartsch G, Höltl L, Thurnher M.

Methods Mol Med. 2005;109:71-82.

PMID:
15585914
11.

Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.

Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M.

Clin Cancer Res. 2002 Nov;8(11):3369-76.

12.

An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells.

Schmidhammer S, Ramoner R, Höltl L, Bartsch G, Thurnher M, Zelle-Rieser C.

Urology. 2002 Sep;60(3):521-6.

PMID:
12350510
13.

Defective T-helper cell function after T-cell-depleting therapy affecting naive and memory populations.

Heitger A, Winklehner P, Obexer P, Eder J, Zelle-Rieser C, Kropshofer G, Thurnher M, Holter W.

Blood. 2002 Jun 1;99(11):4053-62.

PMID:
12010807
14.

Human monocyte-derived dendritic cells are deficient in prostaglandin E2 production.

Zelle-Rieser C, Ramoner R, Artner-Dworzak E, Casari A, Bartsch G, Thurnher M.

FEBS Lett. 2002 Jan 30;511(1-3):123-6.

15.
16.

Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma.

Zelle-Rieser C, Barsoum AL, Sallusto F, Ramoner R, Rohrer JW, Höltl L, Bartsch G, Coggin JH JR, Thurnher M.

J Urol. 2001 May;165(5):1705-9.

PMID:
11342960
17.

The disabled dendritic cell.

Thurnher M, Zelle-Rieser C, Ramoner R, Bartsch G, Höltl L.

FASEB J. 2001 Apr;15(6):1054-61.

PMID:
11292667
18.

Supplemental Content

Loading ...
Support Center